RBC Affirms Aerie Pharma (AERI) at 'Outperform'; Positive on Data from Another Rho Kinase Inhibitor
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
RBC Capital is out positive on Aerie Pharmaceuticals (Nasdaq: AERI) amid a recent AAO update. The firm has AERI at Outperform with a price target of $55.
Analyst Adnan Butt commented today:
Data from another rho kinase inhibitor shows improved efficacy over Avastin when combined in DME patients, which could be an additional opportunity for Rhopressa as well. This also means there could be unrealized value in AERI’s compound library that a potential acquirer may pay for on top of Rhopressa/Roclatan. Furthermore, experts on a glaucoma panel thought Roclatan’s 1.5 mmHg difference in efficacy is clinically meaningful.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Raises Price Target on Akamai Technologies (AKAM) to $67 Following Solid 3Q
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!